Evonik is investing in NUMAFERM
Start-up makes the production of peptides more efficient
Currently, peptides are used above all as pharmaceutical or cosmetic active ingredients. In addition to their role as active pharmaceutical ingredients, peptides and proteins in general are a commercially interesting class of molecules, which are used in a variety of medical, cosmetic, and nutritional-physiological applications. The corresponding markets are the focus of the Health & Care growth engine at Evonik. Of particular interest are applications such as ingredients for cell culture media and for nutritional supplements or medical nutrients. Evonik is advancing the industrial use of peptides through its Specialty Additives growth engine.
The production of peptides, which are usually produced through chemical synthesis, is expensive. The reasons for this are the high quantities of raw materials needed, the complex process steps, and the usually low yields. NUMAFERM has now developed a technology platform, which enables plannable biotechnological production of peptides at higher yields and at lower costs. The technology can be used for almost all peptides, and production on an industrial scale .
“The technology can be used for almost all peptides, and production on an industrial scale becomes possible. As a result, new technical applications for peptides also become realistic for the first time. In HTGF III fund investor EVONIK, NUMAFERM now has a strong partner at its side that will enable it to enter into the implementation phase with a targeted approach,” explains Dr. Philipp Rittershaus, Investment Manager at HTGF.
Initially, NUMAFERM plans to use the fresh capital to drive forward technological development and get the first products to market maturity. “In Evonik we have found a strategic investor with extensive experience in developing innovative technologies and in tapping new markets,” says Christian Schwarz, co-founder and managing director of NUMAFERM.
Schwarz laid the scientific foundations for the technology of NUMAFERM in his doctoral thesis at Heinrich Heine University in Düsseldorf. The company was founded at the start of 2017 as a spin-off of the Institute of Biochemistry. Previously, the project was supported by an EXIST research transfer of the German Federal Ministry for Economic Affairs and Energy, among others.
Other news from the department business & finance
These products might interest you
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.